Oxygen Therapy Market Report 2026

The oxygen therapy market size has grown rapidly in recent years. It will grow from $30.88 billion in 2025 to $34.15 billion in 2026 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to limited availability of oxygen delivery devices, reliance on hospital-based oxygen therapy, rising prevalence of respiratory disorders, lack of portable oxygen systems, dependence on conventional oxygen cylinders.

The oxygen therapy market size is expected to see rapid growth in the next few years. It will grow to $50.71 billion in 2030 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to advancements in portable oxygen concentrators, increasing adoption of home oxygen therapy, integration with digital monitoring systems, growing demand for telehealth and remote care solutions, development of smart automated oxygen delivery devices. Major trends in the forecast period include adoption of portable oxygen concentrators, integration of smart monitoring with oxygen therapy, growth of home-based oxygen therapy, increasing use of automated oxygen delivery systems, expansion of telehealth-enabled oxygen management.

The rising prevalence of respiratory disorders is expected to drive growth in the oxygen therapy market in the coming years. Respiratory disorders are conditions that affect the lungs and other parts of the respiratory system, including tuberculosis, lung cancer, mesothelioma, cystic fibrosis, and asthma. Oxygen therapy supports patients with these conditions by providing supplemental oxygen, which helps relieve shortness of breath and improves overall respiratory function. For example, in February 2023, the American Lung Association reported that more than 34 million Americans suffer from chronic lung illnesses, such as asthma or COPD, including emphysema and chronic bronchitis. Additionally, over 25 million Americans, including more than 4 million children, experience breathing difficulties due to asthma. Therefore, the growing prevalence of respiratory disorders is driving the expansion of the oxygen therapy market.

Companies in the oxygen therapy market are focusing on developing advanced products, such as next-generation portable oxygen concentrators, to gain a competitive edge. These compact devices deliver clinically meaningful oxygen output while being lightweight and energy-efficient, enabling increased patient mobility and independence. For instance, in October 2024, Inogen, Inc., a U.S.-based medical technology company, launched the Inogen Rove 4 portable oxygen concentrator, featuring four pulse-dose settings up to 840 ml/min, a user-friendly design weighing less than 3 lbs, and battery options providing up to 5 hours and 45 minutes of operation. This innovation supports homecare adoption and enhances patient autonomy, though achieving higher continuous flow in lightweight formats remains a challenge.

In January 2023, CAIRE Inc., a U.S.-based medical equipment manufacturer, acquired MGC Diagnostics for an undisclosed amount. This acquisition strengthens CAIRE Inc.'s portfolio in diagnostic technologies and enhances its ability to serve patients with pulmonary diseases. MGC Diagnostics specializes in manufacturing and selling oxygen therapy tools, including pulse oximeters.

Major companies operating in the oxygen therapy market are Smiths Medical Inc., Hersill SL, Fisher & Paykel Healthcare Corporation Limited, Invacare Corporation, Teleflex Incorporated, Koninklijke Philips N.V., Drive Devilbiss International, Allied Healthcare Products Inc., Becton Dickinson and Company, General Electric Company, Getinge Group, Essex Industries Inc., Chart Industries Inc., Drägerwerk AG & Co. KGaA, Gas Control Equipment Group, Thermo Fisher Scientific Inc., OxyBand Technologies Inc., Nidek Medical Products Inc., Linde Healthcare, Taiyo Nippon Sanso Corporation, Inogen Inc., Heinen + Löwenstein GmbH & Co. KG, Messer Medical Austria GmbH, TECNO-GAZ S.p.A, HUM - Gesellschaft für Homecare und Medizintechnik mbH, medicap homecare GmbH, GCE Holding AB, Salter Labs, Vyaire Medical Inc., CAIRE Inc., Precision Medical Inc., O2 Concepts LLC, AirSep Corporation.

North America was the largest region in the oxygen therapy market in 2025. The regions covered in the oxygen therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oxygen therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the oxygen therapy market by raising costs of imported oxygen concentrators, delivery devices, and cylinders. Hospitals, home care providers, and post-acute care centers in regions such as north america, europe, and asia-pacific are most impacted due to dependency on imported equipment. While tariffs have slightly increased procurement costs, they have encouraged local manufacturing, stimulated innovation in domestic oxygen therapy solutions, and enhanced the availability of cost-efficient oxygen delivery devices.

The oxygen therapy market research report is one of a series of new reports that provides oxygen therapy market statistics, including oxygen therapy industry global market size, regional shares, competitors with a oxygen therapy market share, detailed oxygen therapy market segments, market trends and opportunities, and any further data you may need to thrive in the oxygen therapy industry. This oxygen therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Oxygen therapy is the administration of supplemental oxygen to individuals with respiratory conditions who cannot obtain sufficient oxygen naturally due to various diseases or health issues. It ensures that patients with lung disorders or breathing difficulties receive the oxygen necessary for proper body function.

The main oxygen therapy products include oxygen delivery devices and oxygen source equipment. Oxygen delivery devices are secondary equipment that provide oxygen to patients who cannot maintain safe oxygen saturation levels. These include respiratory support devices such as nasal or transtracheal catheters and nasal cannulas. Oxygen therapy equipment can be stationary or portable and is applied in conditions such as pneumonia, chronic obstructive pulmonary disease (COPD), asthma, obstructive sleep apnea, respiratory distress syndrome, cystic fibrosis, and others. These products are used in hospitals, clinics, home care, and post-acute care settings.

The oxygen therapy market consists of sales of pulse oximeters, oxygen flow meters, portable oxygen supply devices, nasal cannulas, simple masks, non-rebreather masks, continuous positive airway pressure, BiPAP, bag valve mask (ambu bag), endotracheal intubation, and mechanical ventilator. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.